Cover Image
市場調查報告書

耳鳴:開發中產品分析

Tinnitus - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200496
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
耳鳴:開發中產品分析 Tinnitus - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 62 Pages
簡介

耳鳴是指耳邊和腦中各種感到像有噪音的症狀。人們生活中常會感到耳鳴。根據NIDCD(國立聽覺·傳達障礙研究所)指出,約有12%的65∼74歲的男性有耳鳴。白人發病率更高,此外美國南部、東北發病率約為全美平均約二倍。

本報告提供全球各國治療耳鳴所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等資訊。

簡介

  • 調查範圍

耳鳴概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

耳鳴:企業開發中的治療藥

耳鳴:大學/機關研究中的治療藥

耳鳴:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

耳鳴:企業開發中的產品

耳鳴:大學/機關研究中的產品

耳鳴的治療藥的開發企業

  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Flexion Therapeutics, Inc.
  • Knopp Biosciences LLC
  • Merz Pharma GmbH & Co. KgaA
  • Otonomy, Inc.
  • SciFluor Life Sciences, LLC
  • Sound Pharmaceuticals, Inc.
  • Synphora AB

耳鳴:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • acamprosate calcium
  • AM-102
  • AUT-00063
  • AUT-3
  • esketamine hydrochloride
  • gacyclidine SR
  • latanoprost
  • neramexane mesylate
  • SF-0034
  • 小分子
  • SPI-1005
  • SPI-3005

耳鳴:最近的開發平台趨勢

耳鳴:暫停中的計劃

耳鳴:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8447IDB

Summary

Global Markets Direct's, 'Tinnitus - Pipeline Review, H2 2016', provides an overview of the Tinnitus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tinnitus
  • The report reviews pipeline therapeutics for Tinnitus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tinnitus therapeutics and enlists all their major and minor projects
  • The report assesses Tinnitus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tinnitus

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tinnitus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tinnitus Overview
  • Therapeutics Development
    • Pipeline Products for Tinnitus - Overview
    • Pipeline Products for Tinnitus - Comparative Analysis
  • Tinnitus - Therapeutics under Development by Companies
  • Tinnitus - Therapeutics under Investigation by Universities/Institutes
  • Tinnitus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Tinnitus - Products under Development by Companies
  • Tinnitus - Products under Investigation by Universities/Institutes
  • Tinnitus - Companies Involved in Therapeutics Development
    • AudioCure Pharma GmbH
    • Auris Medical Holding AG
    • Knopp Biosciences LLC
    • Merz Pharma GmbH & Co. KgaA
    • Otonomy, Inc.
    • SciFluor Life Sciences, LLC
    • Sound Pharmaceuticals, Inc.
  • Tinnitus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AM-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Activate KCNQ for Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • esketamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gacyclidine SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neramexane mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-0034 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-1005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-3005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tinnitus - Dormant Projects
  • Tinnitus - Product Development Milestones
    • Featured News & Press Releases
      • Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
      • Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million
      • Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
      • Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus
      • Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus
      • Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City
      • Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus
      • Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311
      • Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
      • Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio
      • Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
      • Apr 20, 2015: Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals
      • Mar 13, 2015: Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus
      • Mar 11, 2015: Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City
      • Mar 10, 2015: Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tinnitus, H2 2016
  • Number of Products under Development for Tinnitus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Tinnitus - Pipeline by AudioCure Pharma GmbH, H2 2016
  • Tinnitus - Pipeline by Auris Medical Holding AG, H2 2016
  • Tinnitus - Pipeline by Knopp Biosciences LLC, H2 2016
  • Tinnitus - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
  • Tinnitus - Pipeline by Otonomy, Inc., H2 2016
  • Tinnitus - Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Tinnitus - Pipeline by Sound Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Tinnitus - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Tinnitus, H2 2016
  • Number of Products under Development for Tinnitus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top